Effects of beta-aminopropionitrile on equine tendon metabolism in vitro and on effects of insulin-like growth factor-I on matrix production by equine tenocytes.

This research study examines the impact of beta-aminopropionitrile and insulin-like growth factor (IGF)-I on equine tendon cells in order to decipher their roles in tendon healing processes. It was found that while IGF-I stimulated collagen production, beta-aminopropionitrile impeded collagen synthesis and could possibly impair tendon healing at a cellular level.

Methodology

• The study used flexor tendon samples from three horses to conduct the experiment.
• These tendon samples were exposed to four different treatments, which include control (no treatment), IGF-I only, beta-aminopropionitrile only, and a combination of IGF-I and beta-aminopropionitrile.
• The duration of the treatment lasted for 10 days. Following this, the research team evaluated mRNA message expression levels for two types of collagen: type I and type III.
• In addition to this, histologic examinations, protein synthesis, and calculations of glycosaminoglycan, DNA, and new collagen synthesis were performed.

Results

• IGF-I stimulated an anabolic response, a process where larger molecules are synthesized from smaller ones, in the tendon. This led to increased levels of collagen synthesis along with increased DNA content and glycosaminoglycan levels.
• On the other hand, beta-aminopropionitrile significantly suppressed collagen synthesis. This suppression could not be mitigated by the simultaneous treatment with IGF-I.
• Beta-aminopropionitrile also altered cell morphology, resulting in large, round cells with nuclei positioned to the side and diminished density of collagen fibres.
• Protein production and collagen type-III mRNA expression, which helps in collagen synthesis, were also reduced in these cells.

Conclusion

• Beta-aminopropionitrile treatment resulted in reduced protein and collagen production, which may inhibit tendon healing.
• Furthermore, the negative effects of beta-aminopropionitrile could not be countered by the simultaneous introduction of IGF-I.
• Treatment with beta-aminopropionitrile leads to changes in cell shape and matrix consistency, which could further delay tendon healing. This is because it may reduce collagen production or speed up the degradation of the existing matrix at a cellular level.
• The alterations in collagen content and structure due to beta-aminopropionitrile treatment – in combination with transiently depleted tensile strength – may weaken the healing tendon due to reduced crosslinking.